Research programme: metabolic disorders therapeutics - Catalyst Biosciences/Pfizer

Drug Profile

Research programme: metabolic disorders therapeutics - Catalyst Biosciences/Pfizer

Latest Information Update: 19 Jun 2015

Price : $50

At a glance

  • Originator Catalyst Biosciences; Wyeth
  • Developer Catalyst Biosciences; Pfizer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Metabolic disorders

Most Recent Events

  • 15 Oct 2009 Wyeth has been acquired by Pfizer
  • 07 Aug 2009 Preclinical development is ongoing
  • 10 Jan 2007 Preclinical trials in Metabolic disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top